On 2 August 2007, orphan designation (EU/3/07/465) was granted by the European Commission to The Weinberg Group LLC, United kingdom, for L-threo-3,4-dihydroxyphenylserine for the treatment of orthostatic hypotension in patients with pure autonomic failure.
The sponsorship was transferred to The Weinberg Group Limited, United Kingdom, in March 2009, to Diamond BioPharm Limited, United Kingdom, in March 2011 and to H. Lundbeck A/S, Denmark, in December 2015.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2022 on request of the Sponsor.
Treatment of orthostatic hypotension in patients with pure autonomic failure
|Orphan designation status||
|EU designation number||
|Date of designation||
H. Lundbeck A/S
Documents related to this orphan designation evaluation
EU/3/07/465: Committee for Orphan Medicinal ProductsPublic summary of positive opinion for orphan designation of L-threo-3,4-dihydroxyphenylserine for the treatment of orthostatic hypotension in patients with pure auto... (PDF/219.81 KB)
First published: 28/08/2009
Last updated: 28/01/2022
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: